Nile Pharmaceuticals results, Q3 2023
Net profit, assets, equity and cash flow for Q3 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit32.17 millionEGP · +18.3% vs the same period a year earlier
Total assets988 millionEGP · +26.7% vs the same period a year earlier
Shareholders' equity469 millionEGP · +15.0% vs the same period a year earlier
Operating cash flow-49.84 millionEGP · −1326.0% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Q3 2023 was about 32.17 million EGP, up +18.3% from 27.21 million EGP in Q3 2022.
- Total assets at the end of Q3 2023 were about 988 million EGP, and shareholders' equity about 469 million EGP.
- Operating cash flow for Q3 2023 was negative at 49.84 million EGP.
Key lines against the same period a year earlier
This periodQ3 2022Change
Net profit32.17 million27.21 million+18.3%
Gross profit-94.93 million70.5 million−234.6%
Total assets988 million780 million+26.7%
Total liabilities520 million372 million+39.5%
Shareholders' equity469 million408 million+15.0%
Total liabilities and equity988 million780 million+26.7%
Operating cash flow-49.84 million4.07 million−1326.0%
Investing cash flow31.38 million-2.51 million+1348.5%
Financing cash flow-1.77 million9.27 million−119.1%
Net change in cash-20.24 million10.83 million−287.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy